Wealth Alliance Advisory Group LLC Lowers Stock Position in Pfizer Inc. $PFE

Key Points

• Wealth Alliance Advisory Group LLC reduced its stake in Pfizer by 48.6%, selling 15,380 shares during the second quarter, which brought its total holdings to 16,248 shares worth approximately $394,000.
• Pfizer reported a strong quarterly performance with $14.65 billion in revenue, beating analysts' expectations, and an EPS of $0.78, exceeding the consensus estimate of $0.58.
• The company recently announced a quarterly dividend of $0.43, which represents an annualized yield of 7.2% and demonstrates a high payout ratio of 91.49%.

Wealth Alliance Advisory Group LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 48.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,248 shares of the biopharmaceutical company's stock after selling 15,380 shares during the quarter. Wealth Alliance Advisory Group LLC's holdings in Pfizer were worth $394,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in PFE. Brighton Jones LLC grew its holdings in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. Triumph Capital Management grew its holdings in Pfizer by 20.0% during the 4th quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company's stock worth $273,000 after acquiring an additional 1,717 shares during the last quarter. ProShare Advisors LLC grew its holdings in Pfizer by 15.0% during the 4th quarter. ProShare Advisors LLC now owns 904,859 shares of the biopharmaceutical company's stock worth $24,006,000 after acquiring an additional 118,216 shares during the last quarter. Finally, Raiffeisen Bank International AG bought a new stake in Pfizer during the 4th quarter worth approximately $1,027,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Down 3.8%

PFE traded down $0.95 during trading on Friday, hitting $23.91. 81,158,118 shares of the company's stock were exchanged, compared to its average volume of 37,472,864. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business's 50 day moving average is $24.79 and its two-hundred day moving average is $24.27. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The stock has a market cap of $135.94 billion, a P/E ratio of 12.72, a PEG ratio of 0.85 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the company posted $0.60 earnings per share. The business's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer's dividend payout ratio is presently 91.49%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PFE. Morgan Stanley upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Bank of America upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. HSBC reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Finally, Berenberg Bank dropped their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.